Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of ka...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Malin S., Hallner, Alexander, Brune, Mats, Nilsson, Staffan, Thorén, Fredrik B., Martner, Anna, Hellstrand, Kristoffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012093/
https://www.ncbi.nlm.nih.gov/pubmed/31242079
http://dx.doi.org/10.1080/21645515.2019.1636598
_version_ 1783496189151281152
author Nilsson, Malin S.
Hallner, Alexander
Brune, Mats
Nilsson, Staffan
Thorén, Fredrik B.
Martner, Anna
Hellstrand, Kristoffer
author_facet Nilsson, Malin S.
Hallner, Alexander
Brune, Mats
Nilsson, Staffan
Thorén, Fredrik B.
Martner, Anna
Hellstrand, Kristoffer
author_sort Nilsson, Malin S.
collection PubMed
description Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.
format Online
Article
Text
id pubmed-7012093
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-70120932020-02-24 Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype Nilsson, Malin S. Hallner, Alexander Brune, Mats Nilsson, Staffan Thorén, Fredrik B. Martner, Anna Hellstrand, Kristoffer Hum Vaccin Immunother Commentary Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2. Taylor & Francis 2019-07-24 /pmc/articles/PMC7012093/ /pubmed/31242079 http://dx.doi.org/10.1080/21645515.2019.1636598 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Nilsson, Malin S.
Hallner, Alexander
Brune, Mats
Nilsson, Staffan
Thorén, Fredrik B.
Martner, Anna
Hellstrand, Kristoffer
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
title Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
title_full Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
title_fullStr Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
title_full_unstemmed Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
title_short Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
title_sort immunotherapy with hdc/il-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012093/
https://www.ncbi.nlm.nih.gov/pubmed/31242079
http://dx.doi.org/10.1080/21645515.2019.1636598
work_keys_str_mv AT nilssonmalins immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype
AT hallneralexander immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype
AT brunemats immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype
AT nilssonstaffan immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype
AT thorenfredrikb immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype
AT martneranna immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype
AT hellstrandkristoffer immunotherapywithhdcil2maybeclinicallyefficaciousinacutemyeloidleukemiaofnormalkaryotype

Ejemplares similares